Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population

Summary

Occlusive coronary thrombus formation superimposed on an atherosclerotic plaque is the ultimate event leading to myocardial infarction (MI). Therefore, haemostatic proteins may represent important players in the pathogenesis of MI. It was the objective of this study to evaluate, in a comprehensive way, the role of haemostatic gene polymorphisms in predisposition to premature MI. A total of 810 single nucleotide polymorphisms (SNPs) in 37 genes were assessed for association with MI in a large cohort (1,670 males, 210 females) of Italian patients who suffered from an MI event before the age of 45, and an equal number of controls. Thirty-eight SNPs selected from the literature were genotyped using the SNPlex technology, whereas genotypes for the remaining 772 SNPs were extracted from a previous genome-wide association study. Genotypes were analysed by a standard case-control analysis corrected for classical cardiovascular risk factors, and by haplotype analysis. A weighted Genetic Risk Score (GRS) was calculated. Evidence for association with MI after covariate correction was found for 35 SNPs in 12 loci: F5, PROS1, F11, ITGA2, F12, F13A1, SERPINE1, PLAT, VWF, THBD, PROCR, and F9. The weighted GRS was constructed by including the top SNP for each of the 12 associated loci. The GRS distribution was significantly different between cases and controls, and subjects in the highest quintile had a 2.69-fold increased risk for MI compared with those in the lowest quintile. Our results suggest that a GRS, based on the combined effect of several risk alleles in different haemostatic genes, is associated with an increased risk of MI.

Keywords

Association study - common genetic variants - early-onset myocardial infarction - genetic risk score - haemostatic gene pathway

• References

• 1 Naghavi M, Libby P, Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
• 2 Danesh J, Collins R, Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477-1482.
• 3 Pradhan AD, LaCroix AZ, Langer RD. et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004; 110: 292-300.
• 4 Smith A, Patterson C, Yarnell J. et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112: 3080-3087.
• 5 Rosendaal FR, Varekamp I, Smit C. et al. Mortality and causes of death in Dutch haemophiliacs, 1973–86. Br J Haematol 1989; 71: 71-76.
• 6 Triemstra M, Rosendaal FR, Smit C. et al. Mortality in patients with hemophilia: changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-827.
• 7 Aronson DL. Cause of death in hemophilia A patients in the United States from 1968 to 1979. Am J Hematol 1988; 27: 7-12.
• 8 Eitzman DT, Westrick RJ, Shen Y. et al. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 2005; 111: 1822-1825.
• 9 Kathiresan S, Yang Q, Larson MG. et al. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2006; 26: 1405-1412.
• 10 Zee RYL, Cook NR, Cheng S. et al. Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost 2006; 4: 341-348.
• 11 Smith NL, Bis JC, Biagiotti S. et al. Variation in 24 hemostatic genes and associations with non-fatal myocardial infarction and ischemic stroke. J Thromb Haemost 2008; 6: 45-53.
• 12 Morgan TM, Krumholz HM, Lifton RP. et al. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. J Am Med Assoc 2007; 297: 1551-1561.
• 13 Shiffman D, O'Meara ES, Bare LA. et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008; 28: 173-179.
• 14 van der Krabben MD, Rosendaal FR, van der Bom JG. et al. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008; 6: 720-725.
• 15 Ioannidis JP, Trikalinos TA, Ntzani EE. et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361: 567-571.
• 16 Musunuru K, Kathiresan S. Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 2010; 11: 91-108.
• 17 Ye Z, Liu EHC, Higgins JPT. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
• 18 Mannucci PM, Asselta R, Duga S. et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost 2010; 8: 2116-2121.
• 19 Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-1122.
• 20 Kathiresan S, Voight BF, Purcell S. et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
• 21 Purcell S, Neale B, Todd-Brown K. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
• 22 Wigginton JE, Cutler DJ, Abecasis GR. A Note on exact Tests of Hardy-Weinberg Equilibrium. Am J Hum Genet 2005; 76: 887-893.
• 23 Breslow NE, Day NE. Statistical methods in cancer research: The design and analysis of cohort studies. IARC Sci Publ 1987; 82: 289-302.
• 24 Barrett JC, Fry B, Maller J. et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
• 25 Lin X, Song K, Lim N. et al. Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score – the CoLaus Study. Diabetologia 2009; 52: 600-608.
• 26 Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7: 781-791.
• 27 Shen LL, Hermans J, McDonagh J. et al. Effects of calcium ion and covalent cross-linking on formation and elasticity of fibrin cells. Thromb Res 1975; 6: 255-265.
• 28 Shafey M, Anderson JL, Scarvelis D. et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007; 97: 635-641.
• 29 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS. et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-10216.
• 30 Medina P, Navarro S, Corral J. et al. Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica 2008; 93: 1358-1363.
• 31 Tang W, Basu S, Kong X. et al. Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. Blood 2010; 116: 5032-5036.
• 32 Pintao MC, Roshani S, DE Visser MC. et al. High levels of protein C are determined by PROCR haplotype 3. J Thromb Haemost 2011; 9: 969-976.
• 33 Reiner AP, Carty CL, Jenny NS. et al. PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study. J Thromb Haemost 2008; 6: 1625-1632.
• 34 Saposnik B, Reny JL, Gaussem P. et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103: 1311-1318.
• 35 Smith NL, Chen MH, Dehghan A. et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-1392.
• 36 Ireland HA, Cooper JA, Drenos F. et al. FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men. Arterioscler Thromb Vasc Biol 2009; 29: 1968-1974.
• 37 Cornelis MC, Qi L, Zhang C. et al. Joint effects of common genetic variants on the risk for type 2 diabetes in US men and women of European ancestry. Ann Intern Med 2009; 150: 541-550.
• 38 International Schizophrenia Consortium. Purcell SM, Wray NR, Stone JL. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
• 39 Demirkan A, Penninx BW, Hek K. et al. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol Psychiatry 2011; 16: 773-783.
• 40 Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
• 41 Nicodemus KK, Liu W, Chase GA. et al. Comparison of type I error for multiple test corrections in large single-nucleotide polymorphism studies using principal components versus haplotype blocking algorithms. BMC Genet 2005; 6 (Suppl. 01) S78.
• 42 Ripatti S, Tikkanen E, Orho-Melander M. et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010; 376: 1393-1400.